Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Tirbanibulin Ointment 1% for Actinic Keratosis on Face or Scalp (100 cm2)
NCT05279131Phase 3Completed
- Sponsor
- Almirall
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tirbanibulin in actinic keratosis (AK), sponsored by Almirall. Primary endpoints: Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs at Day 5, Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs at Day 8 and 22 more. Started Jun 2022; status: completed.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT05279131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279131.